Promising cancer treatments

Israel’s Purple Biotech has two promising treatments for solid tumors in clinical (human) trials. CM24 has completed Phase 1 and is in Phase 2 for Pancreatic cancer. NT219 is in Phase 1/2 in the USA. Purple is also partnering Mor, the technology transfer subsidiary of Israel’s Clalit.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *